Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
J Clin Hypertens (Greenwich). 2011 Sep;13(9):677-86. doi: 10.1111/j.1751-7176.2011.00518.x. Epub 2011 Jul 27.
• The angiotensin receptor blockers are highly effective antihypertensive agents that are also particularly well tolerated. • There are no major differences in efficacy or other clinical characteristics among older drugs in this class, although some of the newer agents may more effectively reduce blood pressure than older agents. • Major randomized clinical trials have demonstrated that angiotensin receptor blockers provide significant outcomes benefits in conditions such as diabetic nephropathy, chronic heart failure or heart failure following myocardial infarction, hypertension with left ventricular hypertrophy and in patients whose histories of previous events or complicated diabetes puts them at high cardiovascular risk. • In treating hypertension, angiotensin receptor blockers can be used as first-line therapy or added at later stages of treatment titration. • These drugs are very effective in combination with thiazide diuretics or calcium channel blockers and there are several single-pill, fixed-dose combinations of angiotensin receptor blockers with hydrochlorothiazide, amlodipine, or aliskiren. These combinations can be given as initial therapy (where appropriate) or later in the course of treatment. Three-drug combinations (angiotensin receptor blocker plus amlodipine plus hydrochlorothiazide and angiotensin receptor blocker plus aliskiren plus hydrochlorothiazide) are also available.
血管紧张素受体阻滞剂是一种高效的降压药,且具有很好的耐受性。
该类药物中,旧药与新药在疗效或其他临床特征方面没有明显差异,但一些新型药物可能比旧药更有效地降低血压。
主要的随机临床试验表明,血管紧张素受体阻滞剂在糖尿病肾病、慢性心力衰竭或心肌梗死后心力衰竭、左心室肥厚伴高血压以及有既往事件史或复杂糖尿病使患者处于高心血管风险的情况下,能提供显著的获益。
在治疗高血压时,血管紧张素受体阻滞剂可作为一线治疗药物,也可在治疗滴定的后期阶段添加。
这些药物与噻嗪类利尿剂或钙通道阻滞剂联合使用非常有效,并且有几种血管紧张素受体阻滞剂与氢氯噻嗪、氨氯地平或阿利克仑的单片固定剂量组合。这些组合可作为初始治疗(在适当的情况下)或在治疗过程的后期使用。还可使用三药组合(血管紧张素受体阻滞剂加氨氯地平加氢氯噻嗪和血管紧张素受体阻滞剂加阿利克仑加氢氯噻嗪)。